6.1
The committee considered that further research into the clinical effectiveness of natalizumab for the treatment of highly active relapsing–remitting multiple sclerosis in the suboptimal therapy group is needed.
The committee considered that further research into the clinical effectiveness of natalizumab for the treatment of highly active relapsing–remitting multiple sclerosis in the suboptimal therapy group is needed.